TISSUE DONATION IS CRITICAL TO FIND TREATMENTS! Click here to learn more.
We envision a world where Epithelioid Hemangioendothelioma (EHE) is easily diagnosed and treatable. Join our dedicated community by subscribing to our emails.
Upcoming Foundation Events
Quick Links
Patients
Community
Latest EHE News, Events and Research
Advancing our Mission, Representing EHE Patients at ASCO 2024
Our Interim Executive Director and Director of Research, Denise Robinson, recently represented epithelioid hemangioendothelioma (EHE) patients at the 2024 ASCO Annual Meeting in Chicago, Illinois, where nearly 40,000 global oncology professionals convened. The American Society of Clinical Oncology (ASCO), is the world’s leading organization for oncology, bringing together advocates, healthcare providers, and related professionals to […]
Read More
Reflecting on Success: 2024 EHE Fun Run & Walk Recap
With enthusiasm and gratitude, The EHE Foundation is proud to celebrate another successful year of the Annual EHE Fun Run & Walk. This event, dedicated to supporting The EHE Foundation’s mission to find treatments and a cure for epithelioid hemangioendothelioma (EHE), always brings our community together in an extraordinary way! With 1387 registrations, our hearts […]
Read More
Planting Seeds for Future Developments: EHEF Research Grant Grows
The EHE Foundation invests in novel EHE research yearly through its EHE Research Grants Program. The program officially began in 2021, with only a few applicants interested in EHE research. Today, 10 applicants have submitted proposals in our 2024 grants cycle. Along the way, we have had the good fortune to meet and collaborate with […]
Read More
Ikena Oncology IK-930 Update
On May 28, 2024, Ikena Oncology announced they are discontinuing the development of IK-930. We share your frustration and disappointment and understand the devastating impact felt by patients. Following this announcement, we met with Ikena to impress upon them the urgency and importance that patients deriving benefits from IK-930 continue to have access to the […]
Read More
Navigating the Mental Health Challenges of an EHE Diagnosis and Treatment
A cancer diagnosis can be one of the most daunting experiences in life, not just physically, but mentally and emotionally as well. The journey through diagnosis, treatment, and everything in between often feels like a roller coaster, filled with uncertainty, fear, and a range of intense emotions. It’s important to acknowledge these challenges and find […]
Read More
The Pledge: Edition 36, Q1 – January-March, 2024
Publication of The Pledge quarterly newsletter is led by the EHE Rare Cancer Charity (UK). EHE patient advocacy groups from around the globe. provide content including research news, patient and fundraising stories, and much more. Click here to view the most recent edition of our online EHE newsletter, The Pledge.
Read More
Scientific & Medical Advisory Board Collaborates to Improve Outcomes for People Living with EHE
On September 10, 2024, The EHE Foundation held a virtual meeting of our Scientific & Medical Advisory Board (SMAB). The meeting aimed to welcome new members, review current research projects, and discuss future needs and goals to advance EHE research. The meeting began with a warm welcome to new members of the SMAB: Tom Chen, […]
Read More
GDF-15 Predicts Epithelioid Hemangioendothelioma Aggressiveness and is Down-regulated by Sirolimus Through ATF4/ATF5 Suppression
Drs. Silvia Stacchiotti, Sandro Pasquali, and Nadia Zaffaroni (IRCCS – INT, Milan, Italy) and colleagues published their promising findings in Clinical Cancer Research, September 16, 2024. This study, funded in part by The EHE Foundation in partnership with EHE Rare Cancer Charity (UK), aimed to assess the efficacy of sirolimus for the treatment of EHE […]
Read More
Harnessing Cyclin-dependent Kinase Inhibitors to Gain Mechanistic Insight Into the Regulation of the TAZ-CAMTA1 Fusion Protein
Ajay Pobbati, PhD, Brian Rubin, MD, PhD, and colleagues at the Cleveland Clinic published their findings from the study “CDK9 inhibition by dinaciclib is a therapeutic vulnerability in epithelioid hemangioendothelioma” in Clinical Cancer Research, September 13, 2024. This study, funded in part by a grant from The EHE Foundation, provides a strong rationale for investigating […]
Read More